WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy

WestPark Capital initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $4.50.

For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.

Shares of Akebia Therapeutics closed at $0.97 yesterday.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• NV Gold closes final tranche of private placement, raising $1.4M
• Netcapital gets second Nasdaq notice over late financial filings